Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice

British Journal of Pharmacology

Volumn 145, Issue 2, 2005, Pages 219-227

  Oki, Tomomi ^a   Sato, Shuichi ^b   Miyata, Keiji ^b   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Bladder; Muscarinic receptor binding; Oxybutynin; Plasma concentration; Salivary secretion; Solifenacin; Submaxillary gland

Indexed keywords

DEETHYLOXYBUTYNIN; METHYLSCOPOLAMINE; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PILOCARPINE; SOLIFENACIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER; COLON; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; HEART; LUNG; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; SALIVATION; SUBMANDIBULAR GLAND;

ADMINISTRATION, ORAL; ANIMALS; DEPRESSION, CHEMICAL; MALE; MANDELIC ACIDS; MICE; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; RADIOLIGAND ASSAY; RECEPTORS, MUSCARINIC; SALIVARY GLANDS; SALIVATION; TETRAHYDROISOQUINOLINES; URINARY BLADDER;

EID: 19944419494     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706184     Document Type: Article

References (40)

1. ABRAMS, P., CARDOZO, L., FALL, M., GRIFFITHS, D., ROSIER, P., ULMSTEN, U., VAN KERREBROECK, P., VICTOR, A. & WEIN, A. (2002). Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Committee Society. Neurourol. Urodyn., 21, 167-178.
2. ABRAMS, P., FREEMAN, R., ANDERSTROM, C. & MATTIASSON, A. (1998). Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Pharmacol., 81, 801-810.
3. ANDERSSON, K.-E. (1988). Current concepts in the treatment of disorders of micturition. Drugs, 35, 477-494.
4. ANDERSON, R.U., MOBLEY, D., BLANK, B., SALTZSTEIN, D., SUSSET, J. & BROWN, J.S. (1999). Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J. Urol., 161, 1809-1812.
5. BEAUCHAMP, H.T., CHANG, R.S.L., SIGEL, P.K.S. & GIBSON, R.E. (1995). In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency. J. Pharmacol. Exp. Ther., 272, 612-618.
6. BULMER, P. & ABRAMS, P. (2000). The overactive bladder. Rev. Contemp. Pharmacother., 11, 1-11.
7. BYMASTER, F.P., CARTER, P.A., YAMADA, M., GOMEZA, J., WESS, J., HAMILTON, S.E., NATHANSON, N.M., MCKINZIE, D.L. & FELDER, C.C. (2003). Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur. J. Neurosci., 17, 1403-1410.
8. CHAPPLE, C.R. (2000). Muscarinic receptor antagonists in the treatment of overactive bladder. Urology, 55, 33-46.
9. CAULFIELD, M.P. (1993). Muscarinic receptor: characterization, coupling and function. Pharmacol. Ther., 58, 319-379.
10. EGLEN, R.M., REDDY, H., WATSON, N. & CHALLIS, R.A.J. (1994). Muscarinic acetylcholine receptors in smooth muscle. Trends Pharmacol. Sci., 15, 114-119.
11. EHLERT, F.J. & TRAN, L.P. (1990). Regional distribution of M1, M2 and non-M1, non-M2 subtypes of muscarinic binding sites in rat brain. J. Pharmacol. Exp. Ther., 255, 1148-1157.
12. 3 muscarinic receptor single- and double-knockout mice. Mol. Pharmacol., 66, 260-267.
13. GIRALDO, E., MARTOS, F., GOMEZA, A., GARCIA, A., VIGANO, M.A., LADINSKY, H. & SANCHEZ DE LA CUESTA, F. (1988). Characterization of muscarinic receptor subtypes in human tissues. Life Sci., 43, 1507-1515.
14. GUPTA, S.K. & SATHYAN, G. (1999). Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J. Clin. Pharmacol., 39, 289-296.
15. HAMMER, R., BERRIE, C.P., BIRDSALL, N.J.M., BURGEN, A.S.V. & HULME, E.C. (1980). Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature, 283, 90-92.
16. HULME, E.C., BIRDSALL, N.J.M. & BUCKLEY, N.J. (1990). Muscarinic receptor subtypes. Annu. Rev. Pharmacol. Toxicol., 30, 633-673.
17. 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch. Pharmacol., 366, 97-103.
18. 2+ mobilization study in monkey cells. Life Sci., 74, 843-853.
19. 3-receptor antagonist, on experimental models of bowel dysfunction in vivo. Jpn. J. Pharmacol., 86, 281-288.
20. LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 65-275
21. 3 muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. J. Physiol., 558, 561-575.
22. 3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J. Pharmacol. Exp. Ther., 310, 1255-1265.
23. NILVEBRANT, L., ANDERSSON, K.E., GILLBERG, P.G., STAHL, M. & SPARF, B. (1997). Tolterodine - a new bladder-selective antimuscarinic agent. Eur. J. Pharmacol., 327, 195-207.
24. 1-adrenoceptors in rat tissues in relation to the plasma concentration. Life Sci., 63, 2147-2155.
25. OHTAKE, A., UKAI, M., HATANAKA, T., KOBAYASHI, S., IKEDA, K., SATO, S., MIYATA, K. & SASAMATA, M. (2004). In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur. J. Pharmacol., 492, 243-250.
26. OKI, T., KAWASHIMA, A., UCHIDA, M. & YAMADA, S. (2005). In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin. Life Sci., (in press).
27. OKI, T., KIMURA, R., SAITO, M., MIYAGAWA, I. & YAMADA, S. (2004). Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J. Urol., 172, 2059-2064.
28. TAKEUCHI, J., FULTON, J., JIA, Z., ABRAMOV-NEWERLY, W., JAMOT, L., SUD, M., COWARD, D., RALPH, M., RODER, J. & YEOMANS, J. (2002). Increased drinking in mutant mice with truncated M5 muscarinic receptor genes. Pharmacol. Biochem. Behav., 72, 117-123.
29. UCHIDA, S., YAMADA, S., OHKURA, T., HESHIKIRI, M., YOSHIMI, A., SHIRAHASE, H. & KIMURA, R. (1995). The receptor occupation and plasma concentration of NKY-722, a water-soluble dihydropyridine-type calcium antagonist, in spontaneously hypertensive rats. Br. J. Pharmacol., 114, 217-223.
30. VAN ROSSUM, J.M., HURKMANS, J.A.T.M. & WOLTERS, C.J.J. (1963). Cumulative dose-response curves II. Techniques for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch. Int. Pharmacodyn., 143, 299-330.
31. 4) in rat forebrain. Mol. Pharmacol., 38, 267-273.
32. WALDECK, K., LARSSON, B. & ANDERSSON, K.-E. (1997). Comparison of oxybutynin and its metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J. Urol., 157, 1093-1097.
33. WANG, P., LUTHIN, G.R. & RUGGIERI, M.R. (1995). Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J. Pharmacol. Exp. Ther., 273, 959-966.
34. WEIN, A.J. (1990). Pharmacologic treatment of incontinence. J. Am. Geriatr. Soc., 38, 317-325.
35. 35S]GTPγS in rat brain and spinal cord. Br. J. Pharmacol., 139, 1462-1468.
36. YAMADA, S., NAKAJIMA, M., KUSAKA, T., UCHIDA, S. & KIMURA, R. (2002). In vivo receptor binding of benidipine and amlodipine in mesenteric arteries and other tissues of spontaneously hypertensive rats. Life Sci., 70, 1999-2011.
37. 1A-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J. Pharmacol. Exp. Ther., 296, 160-167.
38. 3H]WB4101: effect of 6-hydroxydomine treatment. J. Pharmacol. Exp. Ther., 215, 176-185.
39. YARKER, Y.E., GOA, K.L. & FITTON, A. (1995). Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging, 6, 243-262.
40. YEOMANS, J., FORSTER, G. & BLAHA, C. (2001). M5 muscarinic receptors are needed for slow activation of dopamine neurons and for rewarding brain stimulation. Life Sci., 68, 2449-2456.